Crossref journal-article
Wiley
British Journal of Haematology (311)
Abstract

Summary.Two hundred and forty‐three patients diagnosed with multiple myeloma (MM) in a single institution over a 22‐year period and treated with standard chemotherapy were analysed in an attempt to determine the impact of response to therapy on survival. The overall response rate in 229 evaluable patients was 50.1% (34.9% objective response plus 15.2% partial response). Median survivals of patients with objective and partial response were 43.4 and 42.8 months, respectively, versus 19 months for nonresponders. Median survival of 14 patients who achieved a complete remission was 42 months, whereas in 21 rapid responders (≤ 2 months) median survival was 43.3 months. A significant correlation between response and survival was observed with the landmark (P = 0.0169), the Mantel & Byar (P = 0.0001) and the Cox regression model (P < 0.0001) methods. These results indicate that, in responding patients, neither the degree of response nor the response kinetics has a significant influence on survival. However, the response to therapy is associated with a significantly longer survival in MM patients.

Bibliography

Bladé, J., López‐Guillermo, A., Bosch, F., Cervantes, F., Reverter, J., Montserrat, E., & Rozman, C. (1994). Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. British Journal of Haematology, 88(1), 117–121. Portico.

Authors 7
  1. Joan Bladé (first)
  2. Armando López‐Guillermo (additional)
  3. Francesc Bosch (additional)
  4. Francisco Cervantes (additional)
  5. Joan‐Carles Reverter (additional)
  6. Emilio Montserrat (additional)
  7. Ciril Rozman (additional)
References 27 Referenced 40
  1. 10.1002/1097-0142(197208)30:2<382::AID-CNCR2820300213>3.0.CO;2-C
  2. 10.1001/jama.1969.03160090040009 / Journal of the American Medical Association / Treatment for multiple myeloma with different melphalan dose regimens by Alexanian R. (1969)
  3. 10.1200/JCO.1983.1.11.710
  4. 10.1182/blood.V79.5.1130.1130
  5. 10.1038/bjc.1988.17
  6. 10.1111/j.1600-0609.1989.tb01503.x / European Journal of Haematology / Melphalan/prednisone versus drug combinations for plasma cell myeloma by Bergsagel D.E. (1989)
  7. 10.1200/JCO.1993.11.6.1165
  8. 10.1200/JCO.1989.7.1.119
  9. {'key': 'e_1_2_1_10_1', 'first-page': '145', 'article-title': 'Proposed guidelines for protocol studies. II. Plasma cell myeloma', 'volume': '4', 'author': 'Chronic Leukemia‐Myeloma Task Force. National Cancer Institute', 'year': '1973', 'journal-title': 'Cancer Chemotherapy Reports'} / Cancer Chemotherapy Reports / Proposed guidelines for protocol studies. II. Plasma cell myeloma by Chronic Leukemia‐Myeloma Task Force. National Cancer Institute (1973)
  10. 10.1111/j.2517-6161.1972.tb00899.x / Journal of the Royal Statistical Society / Regression models and life tables by Cox D.R. (1972)
  11. 10.1016/S0140-6736(80)92941-4
  12. 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
  13. 10.1016/S0140-6736(89)91548-1
  14. 10.1182/blood.V54.1.13.13 / Blood / Improved survival of increased‐risk myeloma patients on combined triple‐alkylating‐agent therapy: a study of the CALGB by Harley J.B. (1979)
  15. 10.1182/blood.V79.11.2827.bloodjournal79112827
  16. 10.1111/j.1365-2141.1969.tb00441.x
  17. 10.1182/blood.V80.7.1666.1666
  18. 10.1080/01621459.1958.10501452
  19. 10.1016/0140-6736(92)90004-M
  20. 10.1016/0197-2456(82)90027-7
  21. 10.1080/01621459.1974.10480131 / Journal of the American Statistical Association / Evaluation of response time data involving transient status: an illustration using heart transplant data by Mantel N. (1974)
  22. 10.1093/oxfordjournals.annonc.a057902
  23. {'key': 'e_1_2_1_24_1', 'first-page': '203', 'article-title': 'Evaluation of intensive (VBMCP) vs standard (MP) therapy for multiple myeloma? (Abstract)', 'volume': '6', 'author': 'Oken M.M.', 'year': '1987', 'journal-title': 'Proceedings of the American Society of Clinical Oncology'} / Proceedings of the American Society of Clinical Oncology / Evaluation of intensive (VBMCP) vs standard (MP) therapy for multiple myeloma? (Abstract) by Oken M.M. (1987)
  24. 10.1200/JCO.1987.5.9.1373
  25. 10.2307/2529177
  26. {'key': 'e_1_2_1_27_1', 'first-page': '456', 'article-title': 'Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group study', 'volume': '1', 'author': 'Salmon S.E.', 'year': '1983', 'journal-title': 'Journal of Clinical Oncology'} / Journal of Clinical Oncology / Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group study by Salmon S.E. (1983)
  27. 10.1016/S0197-2456(83)80011-7
Dates
Type When
Created 17 years, 5 months ago (March 12, 2008, 7:45 a.m.)
Deposited 7 months ago (Jan. 28, 2025, 9:06 p.m.)
Indexed 7 months ago (Jan. 30, 2025, 12:14 a.m.)
Issued 30 years, 11 months ago (Sept. 1, 1994)
Published 30 years, 11 months ago (Sept. 1, 1994)
Published Online 17 years, 5 months ago (March 12, 2008)
Published Print 30 years, 11 months ago (Sept. 1, 1994)
Funders 0

None

@article{Blad__1994, title={Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients}, volume={88}, ISSN={1365-2141}, url={http://dx.doi.org/10.1111/j.1365-2141.1994.tb04986.x}, DOI={10.1111/j.1365-2141.1994.tb04986.x}, number={1}, journal={British Journal of Haematology}, publisher={Wiley}, author={Bladé, Joan and López‐Guillermo, Armando and Bosch, Francesc and Cervantes, Francisco and Reverter, Joan‐Carles and Montserrat, Emilio and Rozman, Ciril}, year={1994}, month=sep, pages={117–121} }